Women with polycystic ovary syndrome.
Conditions
Interventions
Intervention 1: Intervention group: Using atorvastatin in the amount of 40 mg every night after dinner for 6 weeks until the day of egg retrieval. Intervention 2: Control group: Taking 500 mg Glucopha
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: According to the Rotterdam criteria (the presence of two criteria for the diagnosis of polycystic ovaries 1- oligomenorrhea or amenorrhea 2- clinical or laboratory findings of hyperandrogenism 3- the presence of polycystic ovaries in ultrasound examination) the diagnosis of PCOS has been confirmed in them Age 18-40 years Absence of thyroid disorder, Cushing's syndrome, hyperprolactinoma Absence of kidney disease, liver disease, diabetes, lipid profile disorder No history of cardiovascular disease and blood pressure Not using ovarian stimulation drugs or hormonal drugs in the last 3 months Not using insulin-sensitive drugs or lipid profiles in the last 3 months not smoking non-alcoholic No use of addictive substances Not having breast cancer Absence of medicinal contraindications Absence of malabsorption Having a minimally abnormal amount of insulin resistance
Exclusion criteria
Exclusion criteria: Body mass more than 30 kg/m2 Body mass less than 19 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of insulin resistance is measured based on the HOMA index. The amount of fasting insulin is multiplied by the amount of fasting sugar and the resulting number is divided by 22.5, which is equal to 1 in normal people. Timepoint: The amount of insulin resistance is measured once before the intervention in two groups and again after the intervention in two groups. Method of measurement: Measuring insulin resistance: the amount of fasting insulin is multiplied by the amount of fasting sugar and the resulting number is divided by 22.5, which is equal to 1 in normal people. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of MDA (malon-di-aldehyde) in follicular fluid. Timepoint: After the intervention, it is measured in the follicular fluid and compared with the standard value. Method of measurement: Using a commercial measuring kit of malondialdehyde kiazist.;Examination of TAC (Total Antioxidant Capacity) in follicular fluid. Timepoint: After the intervention and comparison with the standard value. Method of measurement: Using a commercial kit to measure TAC is key.;Investigation of catalase changes in follicular fluid. Timepoint: After the intervention and comparison with the standard value. Method of measurement: Using the commercial kit for measuring catalase of Kiazist company.;Measuring changes in oocyte growth factor (GDF-9) in granulosa cells. Timepoint: After the intervention and comparison with the standard value. Method of measurement: Through the expression of the gene of this protein with the help of Realtime PCR.;Changes in oocyte growth factor (BMP15) in granulosa cells. Timepoint: After the intervention and comparison with the standard value. Method of measurement: Through gene expression and Realtime PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSanaz Alaee
Shiraz University of Medical Sciences
Outcome results
None listed